Close

Barclays Upgrades BioCryst Pharma (BCRX) to Overweight

May 5, 2020 5:08 AM EDT Send to a Friend
Barclays analyst Gena Wang upgraded BioCryst Pharma (NASDAQ: BCRX) from Equalweight ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login